BioSpace News Archive

Exo Therapeutics , Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, today announced the completion of a $25 million Series A financing. Investors in the round included Newpath Partners, Novartis Ventur

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of patients has been enrolled in the Company’s Phase 3 VISION-1 study of MicroLine , its proprietary pilocarpine formulation delivered via its Optejet® dispenser, for the improvement in nea

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.

Montfort (Mon4t), an innovative medical startup introduces its real-time, remote neurological monitor.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company’s positive results from a Phase 3 clinical trial of rimegepant for the preventive treatment of migraine in adults.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77242113), an oral interleukin-23 receptor (IL-23R) antagonist peptide.

Heat Biologics, Inc. (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has completed its gp96-based COVID-19 vaccine cell line which is being developed for use as either a standalone vaccine or in combination with other vaccines

HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to HemoShear’s HST5040 oral small molecule for treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA).

Simplify Medical, Inc., a privately-held company focused on cervical spinal disc arthroplasty and developer of the Simplify® Cervical Artificial Disc, today announced its first surgery following the recent FDA approval for 1-level use.

Arcadia, the leading population health management and healthcare intelligence company, announced today that widely-respected independent analyst firm KLAS Research has found that Arcadia is the highest-scoring fully-rated vendor in Clinician Confidence in Data[3] in their new Population Health Data Acquisition and Analysis 2020 Report